Table 2 |
||||
|
Distribution of background, tumor characteristics, and recent mammography in relation to use of menopausal hormone therapy |
||||
|
Never use |
Past use |
Current use |
Missing |
|
|
|
||||
|
Total |
1,788 |
253 |
523 |
96 |
|
Age at diagnosis |
||||
|
50 to 54 years |
154 (9) |
23 (9) |
148 (28) |
20 |
|
55 to 59 years |
320 (18) |
45 (18) |
181 (35) |
32 |
|
60 to 64 years |
381 (21) |
54 (21) |
116 (22) |
19 |
|
65 to 69 years |
521 (29) |
70 (28) |
55 (11) |
15 |
|
70 to 74 years |
412 (23) |
61 (24) |
23 (4) |
10 |
|
P valuea |
0.99 |
<0.0001 |
||
|
Socioeconomic statusb |
||||
|
Low |
961 (54) |
120 (47) |
197 (38) |
57 |
|
High |
811 (46) |
133 (53) |
325 (62) |
39 |
|
Missing |
16 |
0 |
1 |
0 |
|
P valuea |
0.042 |
<0.0001 |
||
|
Recent mammography |
||||
|
Yes |
933 (59) |
147 (64) |
361 (73) |
61 |
|
No |
650 (41) |
83 (36) |
133 (27) |
29 |
|
Missing |
205 |
23 |
29 |
6 |
|
P valuea |
0.15 |
<0.0001 |
||
|
Tumor size |
||||
|
≤ 10 mm |
488 (28) |
59 (24) |
151 (29) |
30 |
|
11 to 20 mm |
759 (43) |
115 (46) |
240 (46) |
39 |
|
21 to 50 mm |
471 (27) |
72 (29) |
120 (23) |
26 |
|
>50 mm |
56 (3) |
3 (1) |
10 (2) |
1 |
|
Missing |
14 |
4 |
2 |
0 |
|
P valuea |
0.17 |
0.15 |
||
|
Lymph node involvement |
||||
|
0 lymph nodes |
1,164 (68) |
164 (67) |
353 (69) |
69 |
|
1 to 3 lymph nodes |
362 (21) |
53 (22) |
113 (22) |
18 |
|
>3 lymph nodes |
187 (11) |
29 (12) |
46 (9) |
7 |
|
Missing |
75 |
7 |
11 |
2 |
|
P valuea |
0.90 |
0.44 |
||
|
Mean number of examined lymph nodes |
10.4 |
10.8 |
10.7 |
|
|
Grade |
||||
|
1 |
164 (14) |
17 (10) |
78 (23) |
13 |
|
2 |
524 (43) |
65 (40) |
133 (39) |
20 |
|
3 |
520 (43) |
81 (50) |
130 (38) |
33 |
|
Missing |
580 |
90 |
182 |
30 |
|
P valuea |
0.23 |
0.0002 |
||
|
Histology |
||||
|
Ductal |
1,314 (74) |
180 (72) |
338 (66) |
69 |
|
Lobular |
186 (11) |
31 (12) |
81 (16) |
11 |
|
Other |
269 (15) |
38 (15) |
93 (18) |
15 |
|
Missing |
19 |
4 |
11 |
1 |
|
P valuea |
0.64 |
0.0004 |
||
|
Estrogen receptor (ER), progesterone receptor (PR) status |
||||
|
ER-PR- |
227 (18) |
37 (19) |
55 (15) |
17 |
|
ER+PR- |
200 (16) |
32 (17) |
40 (11) |
14 |
|
ER-PR+ |
42 (3) |
5 (3) |
23 (6) |
2 |
|
ER+PR+ |
776 (62) |
116 (61) |
240 (67) |
40 |
|
Missing |
543 |
63 |
165 |
23 |
|
P valuea |
0.91 |
0.0044 |
||
|
|
||||
|
Data presented as n (%). Past use, last use at least 6 months before diagnosis; current use, last use <6 months before diagnosis. aTwo-sided global chi-squared P value for past use and current use, respectively, compared with no use of menopausal hormone therapy. bLow level includes blue-collar workers and low-level white-collar workers, whereas high level includes all other categories. |
||||
|
Rosenberg et al. Breast Cancer Research 2008 10:R78 doi:10.1186/bcr2145 |
||||
